

# Cardiac resynchronization therapy in paediatric patients with congenital heart disease: single centre with 10 years of experience

## Original Article

**Cite this article:** Ergul Y, Sevinc Sengul F, Öztürk E, Kafalı HC, Ayyıldız P, Tanıdır IC, Akdeniz HS, Güneş M, Yıldız O, Haydin S, and Güzeltaş A (2021) Cardiac resynchronization therapy in paediatric patients with congenital heart disease: single centre with 10 years of experience. *Cardiology in the Young* **31**: 940–948. doi: [10.1017/S1047951120004795](https://doi.org/10.1017/S1047951120004795)




Received: 8 October 2020  
Revised: 2 December 2020  
Accepted: 8 December 2020  
First published online: 27 January 2021

### Keywords:

Cardiac resynchronization therapy; congenital heart disease; paediatric

### Author for correspondence:

Prof. Y. Ergul, MD, Department of Pediatric Cardiology & Pediatric Electrophysiology, Istanbul Saglik Bilimleri University Mehmet Akif Ersoy Eğitim Araştırma Hastanesi, İstasyon Mahallesi İstanbul Caddesi Bezirganbağçe Mevki 34303 Küçükçekmece, İstanbul, Turkey. Tel: +90 212 692 20 00; Fax: +90 212 471 94 94. E-mail: [yakupergul77@hotmail.com](mailto:yakupergul77@hotmail.com)

Yakup Ergul<sup>1</sup>, Fatma Sevinc Sengul<sup>1</sup>, Erkut Öztürk<sup>1</sup> , Hasan C. Kafalı<sup>1</sup> , Pelin Ayyıldız<sup>1</sup>, Ibrahim C. Tanıdır<sup>1</sup> , Halil S. Akdeniz<sup>2</sup>, Mustafa Güneş<sup>2</sup>, Okan Yıldız<sup>2</sup>, Sertaç Haydin<sup>2</sup> and Alper Güzeltaş<sup>1</sup>

<sup>1</sup>Department of Pediatric Cardiology, Istanbul Saglik Bilimleri University Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Research Hospital, Istanbul, Turkey and <sup>2</sup>Department of Cardiovascular Surgery, Istanbul Saglik Bilimleri University Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Research Hospital, Istanbul, Turkey

### Abstract

**Objectives:** In recent years, cardiac resynchronization therapy (CRT) has also started to be performed in the paediatric and CHD population. This study aimed to evaluate the efficacy of CRT in children with CHD. **Patients and methods:** Patients with CHD who underwent CRT treatment in our paediatric cardiology clinic between January, 2010 and January, 2020 were included in the study. Demographic findings, 12-lead electrocardiograms, echocardiograms, clinical characteristics, management strategies, and outcomes were reviewed systematically. **Results:** The study population consisted of 18 CHD patients who had been treated with CRT for 10 years in our institution. The median age was 11 years (2.2–18 years) and the median weight was 39 kg (10–81 kg). Systemic ventricle was left ventricle in 13 patients, right ventricle in 4 patients, and 1 patient had single-ventricle physiology. CRT implantation indications were as follows: dysfunction after permanent pacemaker in 11 patients, dysfunction after left bundle branch block in 4 patients, and systemic ventricular dysfunction in 3 patients. CRT implantation techniques were epicardial (n = 13), hybrid (n = 4), and transvenous (n = 1) methods. QRS duration significantly decreased after CRT implantation (160 versus 124 m/second,  $p < 0.05$ ). Median systemic ventricle ejection fraction (EF) significantly increased after the procedure (30 versus 50%,  $p < 0.05$ ). Fourteen patients (78%) were responders, two patients (11%) were superresponders, and two patients (11%) were non-responders after the CRT treatment. One patient deceased during follow-up. Median follow-up duration was 40 months (6–117 months). **Conclusion:** When electromechanical dyssynchrony occurs in paediatric cases with CHD and developing heart failure, patients should be evaluated in terms of CRT to improve ventricular function. Alternative CRT therapy will be beneficial in these cases that do not improve clinically despite optimal medical treatment.

Cardiac resynchronization therapy (CRT) is one of the treatment options for adult patients with idiopathic or ischaemic cardiomyopathy-related heart failure associated with electromechanical dyssynchrony.<sup>1</sup> Adult guidelines recommend CRT for left ventricular ejection fraction (EF)  $\leq 35\%$ , left bundle branch block (LBBB) morphology, long QRS duration ( $\geq 120$  m/second), and NYHA Class II–IV ambulatory symptoms despite optimal medical therapy.<sup>2</sup> In many adult studies, including randomised multicentre clinical trials, it has been reported that functional capacity improved, mortality, and morbidity associated with heart failure reduced by providing structural and cellular remodelling with normal or near-normal electromechanical activation. However, CRT is not free of morbidity, and around 30% of patients do not have a beneficial response.<sup>3</sup>

CHD is a relatively common condition with an incidence of 4–10 per 1000 live births. CHDs are a heterogeneous group of diseases with a wide spectrum of pathologies and sub-pathologies that all vary widely in the treatment approach.<sup>4</sup> In patients with CHDs, even those who were surgically corrected, the heart is not structurally normal, and signs of heart failure may occur at any time in their lives. In paediatric cases, heart failure treatment is mostly medical or requires heart transplantation at the last step. In these paediatric cases, contrary to adults, the use of CRT in the treatment of heart failure is limited and difficult due to different factors such as the age dependence of the QRS duration, the presence of systemic ventricle in right ventricular morphology as well as left ventricular morphology, the presence of single ventricular physiology, and the lack of treatment guidelines in children.<sup>3,5</sup>

There is a limited number of paediatric studies in the literature investigating the use and effectiveness of CRT in CHD.<sup>3,6</sup> In this study, the methods and effects of CRT application in children with CHD were evaluated.

### Patients and methods

The paediatric cases diagnosed with CHD in our arrhythmia centre between January 1, 2010, and January 1, 2020 were included in this study. Patients who developed cardiomyopathy after pacemaker implantation due to congenital complete atrioventricular (AV) block ( $n = 2$ ), those with primary cardiomyopathy ( $n = 1$ ) and patients with CHD and required CRT treatment over 18 years of age, were excluded from the study. This retrospective study was approved by the institutional ethics committee and was conducted in accordance with the principles of the Declaration of Helsinki.

The data for the study was collected from the electrophysiology database system. A study form was created for each patient including information such as gender, age, cardiac diagnosis, ventricular morphology, CRT application indication, electrocardiographic (ECG) findings, echocardiographic features, and clinical status.

The paediatric patients who had cardiac resynchronization therapy were divided into three groups and CRT indications were defined as follows<sup>7,8</sup>:

- Patients who had previous pacemaker implantation due to AV block and developed pacemaker-induced CMP and ventricular dysfunction during follow-up (who need PM and had EF < 45%). Paced QRS duration >120 m/second and echocardiographic mechanical dyssynchrony findings (intraventricular and interventricular dyssynchrony measurements) were sought in addition to clinical findings and EF.
- In patients with CHD and LBBB, together with clinical findings QRS duration >120 m/second and low EF with intraventricular and interventricular dyssynchrony findings at echocardiography.
- The development of systemic ventricular dysfunction and heart failure during follow-up in ccTGA patients, regardless of functional repair or anatomical repair. Regardless of the degree of right bundle branch block-intraventricular conduction delay, these patients were considered as CRT candidates, since our transplant and assist device treatment options were limited in our country.

The ECG evaluations were performed before the procedure at the post-operative first day, first month, and sixth month and 6 months apart thereafter. Twelve-lead ECG was interpreted electronically with the Muse<sup>®</sup> system (Muse Cardiology Information System, GE Healthcare, California, CA, United States of America). The QRS duration was measured in leads II, V1, and V5–6 for consistency, at a paper speed of 25 mm/second (Fig 1a and b).

Echocardiographic evaluations were performed before the procedure at the post-operative first day, first month, and sixth month and 6 months apart thereafter. Standard views of paediatric echocardiogram were recorded including parasternal (long and short axis), apical (four chamber and five chamber), subcostal, and suprasternal views. In the definition of cardiac morphology, an evaluation was made in the direction of blood flow within the framework of the segmental approach.<sup>9</sup>

In addition to clinical and ECG findings, echocardiographic morphology and functions and dyssynchrony measurements were also performed to determine the indications for CRT and for follow-up<sup>10</sup>;

- For atrioventricular dyssynchrony: LV filling time was measured from transmitral flow recordings by pulsed-wave Doppler echocardiography and AV dyssynchrony was considered in case LV filling time/RR interval <40%.
- For interventricular dyssynchrony: Interventricular mechanical delay (IVMD) was evaluated with pulsed-wave Doppler echocardiography. Interventricular mechanical delay was obtained by calculating the difference between aortic and pulmonary pre-ejection intervals (the time from the onset of QRS to the onset of flow). An IVMD > 40 m/second is considered as interventricular dyssynchrony.

Intraventricular dyssynchrony: M mode echocardiography was preferred for these basal measurements of both LV and RV. From the parasternal short–long-axis view of the ventricle, the time difference between the maximal systolic inward motion of the septal and posterior (lateral) wall was calculated: the so-called septal-to-posterior Wall motion delay (SPWMD). Especially, an SPWMD value of  $\geq 130$  m/second was considered as significant intraventricular dyssynchrony.


Additionally, strain and 3D Echocardiography have been in use for intraventricular dyssynchrony and ventricular functions for the last 4 years. Systemic ventricular functions, shortening fraction (SF%), and ejection fraction (EF%) were evaluated. Simpson method was used to estimate systemic ventricular EF%. For systemic left ventricles, EF was measured by using the 5/6 area  $\times$  length formula, and for systemic right ventricles, the 2/3 area  $\times$  length method was used.<sup>8</sup> An SF % of less than 28% or an EF% of less than 55% indicated systolic dysfunction (Fig 2a–d).

Small patient size (body weight or age), presence of a contraindication for transvenous pacing, single-ventricle physiology, or significant residual intracardiac shunt, etc., were multiple factors to perform transvenous, epicardial, or hybrid CRT selection.


Conventional CRT involves implantation of a transvenous pacing lead into the RV and a left ventricular lead placed transvenously into a coronary sinus branch. However, this method could only be performed in a case due to the characteristics of our patient group. In this patient, the procedure was performed through the left subclavian vein by the Seldinger method. Afterwards, the left ventricular lead was placed into an optimal distal coronary sinus ventricular branch by the retrograde cannulation of the coronary sinus by using a variety of tools and techniques including coronary sinus angiography. Epicardial lead placement was performed via median sternotomy or lateral thoracotomy in patients with low body weight, single ventricular physiology, corrected transposition of great arteries, or uncorrected cardiac defects. In patients undergoing a transvenous lead placement, a left ventricular lead insertion was attempted using conventional techniques. In four patients, an atrial and two ventricular leads were placed by a combined transvenous and epicardial approach (hybrid approach) (Fig 3a–c).

In patients with biventricular physiology or with systemic left ventricle (LV), LV lead was usually placed to the LV posterolateral wall far from obtuse marginal branch or phrenic nerve. In patients with systemic right ventricle, right ventricle (RV) lead was placed to midventricular free wall and LV lead to posterolateral or apical segment. In patients with single ventricle, leads were placed to two farthest points at midventricular level.


The response to CRT was measured by ECG and echocardiographic evaluation, which is defined as a quantitative improvement in ventricular functions. Clinical status was categorised as alive with CRT, alive with loss of CRT functionality, or death. CRT response was determined at 6–12 months after the CRT procedure.



**Figure 1. (a-b)** Patient number 14: 2.2 years old, male patient with ventricular septal defect. History: VSD closure, post-operative complete AV block, dual-chamber epicardial pacemaker implantation, and 12 months after surgery, the patient was admitted with severe left ventricle dysfunction. ECG findings prior to CRT implantation; a sense V pace dual-chamber PM (Sinus tachycardia, LBBB with QRS duration 148 m/second). ECG findings 6 months after CRT implantation; QRS duration 102 m/second.



**Figure 2. (a-d)** Patient number 7: 7.5 years old male patient with ventricular septal defect. History: Transcatheter VSD closure, dilated cardiomyopathy with left bundle branch block. (a) Apical four-chamber view in echocardiography prior to CRT implantation. (b) M mode view in echocardiography prior to CRT implantation. (c) Apical four-chamber view in echocardiography, 6 months after CRT-D implantation. (d) M mode view in echocardiography, 6 months after CRT-D implantation. LA = Left atrium; LV=left ventricle; RA = right atrium; RV = right ventricle.



**Figure 3.** (a–c) CRT implantation techniques. (a) Epicardial CRT-P. (b) Hybrid CRT-D. (c) Transvenous CRT-D. LV: Left ventricle; RA = right atrium; RV = right ventricle.

Shortening of the QRS interval following CRT was predefined as a minimum 10% decrease in QRS duration. Quantitative improvement following CRT was predefined as a minimum 10% proportional increase in systemic ejection fraction (EF) over baseline measurements.<sup>8</sup> Subjective improvement was defined as a decrease in one ordinal point of the pre-CRT NYHA class or Modified Ross Heart Failure Classification.

The patients' post-procedural clinical status was grouped as negative responders, non-responders, responders, or superresponders. "Negative responders" were patients who demonstrate clinical worsening of their disease after CRT implantation and a decrease in EF% after CRT when compared with the baseline value. "Nonresponders" were defined as those with no quantitative improvement in clinical response. Either a subjective improvement or an increase of EF%, at least 10% from baseline value was further defined as "responders". Patients were considered to be "superresponders" if functional recovery and left ventricular EF  $\geq$  50% were concurrently demonstrated.<sup>11</sup> Analyses were performed on an intention-to-treat basis.

### Statistical method

In the study, the distribution of variables was classified by computer analysis. The descriptive statistics were calculated using SPSS version 15 (Statistical Package for the Social Sciences for Windows) program. The demographic variables were reported as mean  $\pm$  standard deviation, median (range), numbers, and percentages. The Wilcoxon test was used for repeated measurements.  $p < 0.05$  was considered statistically significant.

### Results

Eighteen patients were included in the study. The median age was 11 years (range 2.2–18 years) and the median weight was 39 kg (range 10–81 kg).

The ventricular morphologies were systemic left ventricle in 13 patients, systemic right ventricle in 4 patients, and single ventricle in a patient. The cardiac pathologies were as follows: Tetralogy of Fallot ( $n = 2$ ), atrioventricular septal defect ( $n = 1$ ), truncus arteriosus ( $n = 1$ ), mitral valve pathology ( $n = 1$ ), atrial septal defect ( $n = 1$ ), and aortic stenosis ( $n = 1$ ).

Indications for CRT implantation were cardiac dysfunction developed after permanent pacemaker implantation (pacing-induced ventricular dysfunction (PIVD)) in 11 patients, ventricular dyssynchrony developed after LBBB in 4 patients, and systemic ventricular dysfunction in 3 patients. Permanent pacemaker implantation was performed in 11 cases (61%) due to post-operative complete AV block, before CRT. Before CRT implantation,

single-chamber ventricular pacing systems were used in five cases (VVIR), dual-chamber ventricular pacing systems in five cases (DDD), and in one case, single-chamber ventricular pacing was performed and then upgraded to the dual-chamber pacing system.

Half of the patients ( $n = 9$ ) were operated in other cardiac centres and pacemakers were implanted, or LBBB developed, and then they were referred to our centre for CRT.

CRT implantation was performed by epicardial ( $n = 13$ ), hybrid ( $n = 4$ ), and transvenous ( $n = 1$ ) techniques. Cardiac resynchronization therapy–pacemaker (CRT-P) and cardiac resynchronization therapy–defibrillator (CRT-D) type devices were used in 15 and 3 cases, respectively. CRT-D was implanted in three patients with the diagnosis of Fallot tetralogy, ccTGA, and aortic stenosis, respectively. CRT-D was implanted in one of these patients (Fallot tetralogy) also for secondary prophylaxis since he was admitted with cardiac failure and VF-related cardiac arrest. The other two (ccTGA, aortic stenosis) were upgraded to CRT-D for primary prevention due to syncope. Only the patient with aortic stenosis (whose VT was not documented before but had CRT-D implantation due to syncope) had sustained VT episodes during follow-up. He was followed up with medical treatment.

The main characteristics of the cases were summarised in Table 1.

The median cardiothoracic ratio (CTR) after CRT implantation decreased significantly when compared to the pre-procedural median CTR (65 versus 58%,  $p < 0.05$ ).

Median QRS duration after CRT implantation decreased significantly when compared to the pre-procedural QRS duration (160 versus 124 m/second,  $p < 0.05$ ).

The median systemic ventricular EF% increased dramatically after the procedure (30 versus 50%  $p < 0.05$ ).

Fourteen cases were "Responders" (78%), two cases were "superresponders" (11%), and two cases were "nonresponders" (11%). While symptoms (hospitalisation due to cardiac failure, dyspnoea, fatigue, prolonged feeding times with growth failure, exercise intolerance) remained the same or partially recovered in 40% of the patients, significant regression of symptoms was seen in 50% of the patients. Worsening was seen only in two patients (11%). NYHA classification could be evaluated in 10 patients. While worsening was detected in one patient (Class 3–Class 4), four patients remained at the same NYHA class (Class 3 in two patients, Class 2 in one patient, Class 4 in one patient). Improvement was seen in five patients (from Class 4 to Class 2 in one patient, from Class 4 to Class 3 in one patient, from Class 3 to Class 1 in one patient, from Class 3 to Class 2 in two patients). Ross classification could be evaluated in eight patients. While worsening was detected in one patient (Class 3–Class 4), three patients remained at the same Ross class (Class 3 in two

**Table 1.** Baseline characteristics of the patients (n = 18)

Age, years	11 (2.2–18)
Weight, kg	39 (10–81)
Male, gender	14 (77)
CHD population	
Systemic RV	4 (22)
Systemic LV	13 (72)
Single ventricle	1 (6)
Conduction abnormality	
Complete heart block-paced QRS	11 (61)
LBBB	4 (22)
RBBB or intraventricular conduction delay	3 (17)
Conventional pacing pre-CRT	11 (61)
Pre-CRT QRS duration, m/second	160 (95–256)
Pre-CRT EF%	30 (20–45)
Pre-CRT cardiothoracic ratio%	65 (59–76)
CRT implantation techniques	
Epicardial	13 (72)
Transvenous	1 (6)
Hybrid	4 (22)
Type of CRT system, n (%)	
CRT-P	15 (83)
CRT-D	3 (17)
Outcomes after CRT	
Venous thrombosis*	1 (6)
Infection*	1 (6)
Significant increase in capture threshold*	1 (6)
Pocket haematoma*	1 (6)
>10% increase in EF	16 (88)
>10% decrease in QRS duration	17 (94)
Adverse events (arrhythmia or lead failure**)	2 (12)
Death	1 (6)

Values are median (range) or n = (%)

\*Acute complications

\*\*Lead fracture

patients, Class 2 in one patient). Improvement was seen in four patients (from Class 4 to Class 2 in one patient, from Class 4 to Class 3 in one patient, from Class 3 to Class 2 in two patients)

The median follow-up period of the patients was 40 months (6–117 months). Patients were followed up regularly in the outpatient clinic for adverse events. Lead failure was observed in one patient and ventricular tachyarrhythmia in another patient. Failed lead was changed and antiarrhythmic therapy was initiated for ventricular tachyarrhythmia.

One patient died during the follow-up on the cardiac transplantation list. This patient was diagnosed with ventricular septal defect and aortic stenosis at 12 years of age. First, VSD was closed at the age of 1.5. At 10 years of age, the Bentall procedure was performed due to aortic stenosis and aortic valve failure, and dual pacing was performed due to post-operative AV block. Although CRT-D was upgraded via hybrid method due to PIVD, the patient was a non-responder.

The details of CRT procedures and the results of clinical status were summarised in Table 2.

## Discussion

In this study, our CRT results in children with CHD were evaluated. We found that CRT increased the systemic ventricular

systolic functions on echocardiography, shortened the QRS time on ECG, facilitated electromechanical synchronisation, and improved the clinical status of the patients. This study is one of the rare paediatric studies in literature that involves 10 years of data from an arrhythmia centre with a large volume in a developing country.

CRT basically allows to eliminate electromechanical dyssynchrony via synchronous pacing of both ventricles that result in coordinated biventricular contraction, decrease in myocardial strain and myocardial energy expenditure, reverse in adverse remodelling, and reduce in heart failure symptoms.<sup>3,12</sup> The paediatric heart failure population is heterogeneous in both anatomy and aetiology of heart failure; thus, the adult experience cannot easily be applied in paediatrics. Although there is a standard guideline for CRT indications in adults, there is insufficient data for paediatric cases. The main indications reported in the studies for CRT were acute dyssynchronisation and systemic ventricular dysfunction due to acute post-operative period, PIVD, LBBB, and right bundle branch block (RBBB).<sup>5,6</sup>

Dubin et al<sup>13</sup> described a large cohort of paediatric and adult CHD patients in which 103 had CRT devices implanted (median age: 12.8 years). This cohort included 73 patients (71%) with CHD, 16 (15.5%) with cardiomyopathy, and 14 (13.5%) with congenital complete heart block. Almost half (45%) of these individuals had pacemakers prior to the CRT devices. Over the follow-up period (mean: 4.5 months), the QRS duration improved by  $38 \pm 31$  m/second (from  $166 \pm 33$  m/second to  $126 \pm 24$  m/second;  $p < 0.01$ ) and the EF improved by  $14 \pm 13\%$  (from  $26 \pm 12\%$  to  $40 \pm 15\%$ ;  $p < 0.05$ ). Improvements in QRS duration and EF were seen in all three groups, with no significant differences between the outcomes between them.

Janoušek et al<sup>14</sup> described a multicentre cohort of 109 CRT patients with a greater proportion of CHD patients (80%) as compared with those in the study by Dubin et al<sup>13</sup>. Most of the patients in this cohort (77%) had dyssynchrony associated with single-site pacing, although 23% had electrical dyssynchrony with intrinsic atrioventricular nodal conduction. Of these, 9% had LBBB with a systemic LV, 5% had right bundle branch block (RBBB) with a systemic right ventricle (RV) or single ventricle, and 9% had non-specific QRS prolongation. During follow-up (median: 7.5 months), similar improvements in QRS duration (median: 40 ms improvement from a starting median QRS duration of 160 m/second) and EF (median: 12% improvement from a median starting EF of 27%) were seen.

Our follow-up period was quite long when compared with these big series above (median 40 months). PIVD, LBBB, and RBBB were the main CRT indications. In our study, a 20% increase in median EF and a median of 36 m/second decrease in QRS duration was observed.

Complete AV block can develop after operations for DORV, DILV, ccTGA, AVSD, TOF, and VSD. Single-chamber or double-chamber pacemaker implantation is the treatment.<sup>15</sup> It was reported that PIVD might develop in the long term and this was observed to be higher in right ventricular pacing. It has been stated that PIVD, mainly developed as a result of dyssynchronisation and an improvement in ventricular functions could be seen by upgrading to CRT.<sup>16,17</sup> Balaj et al, in their series of 47 cases with post-operative pacemaker implantation (right atrium–right ventricle) who were smaller than 2 years old when the surgery was performed, reported PIVD in 9 patients (19%). They observed an increase in the median FS of these nine cases from 11 to 29% when they were upgraded to CRT.<sup>17</sup>

**Table 2.** Characteristics of the CRT procedures performed in the patients

Patient no.	Age (years)	Diagnosis	CRT indication	CRT technique	CTR% Pre-CRT	CTR% After 6–12 months	QRS Duration Pre-CRT m/second	QRS Duration After 6–12 months m/second	EF% Pre-CRT	EF% After 6–12 months	EF% Final	Clinical* Status	Live	Follow-up (months)
1	11	VSD+ subaortic stenosis	LBBB	Hybrid	65	63	170	134	20	55	60	Responders	Live	13
2	12.5	ccTGA	PM induced	Epicardial	64	59	120	113	38	50	50	Responders	Live	49
3	12	VSD+Aortic stenosis	PM induced	Hybrid	76	69	256	192	30	32	30	Non-responders	Death	19
4	6.5	TOF	PM induced	Epicardial	75	61	224	142	26	44	45	Responders	Live	40
5	17	AVSD	PM induced	Hybrid	62	60	228	188	22	52	50	Responders	Live	51
6	6.0	VSD+ASD	PM induced	Epicardial	74	70	150	126	40	40	45	Non-responders	Live	117
7	7.5	VSD	LBBB	Epicardial	61	52	150	110	35	50	50	Responders	Live	14
8	2.5	Truncus arteriosus	PM induced	Epicardial	68	54	158	100	30	55	55	Responders	Live	111
9	9.5	ccTGA	Ventricular Dysfunction	Epicardial	59	56	160	122	33	40	40	Responders	Live	13
10	14.5	Single ventricle	PM induced	Epicardial	67	57	95	68	30	50	50	Responders	Live	85
11	14	TOF	PM induced	Epicardial	59	57	180	128	31	43	40	Responders	Live	40
12	15.5	Mitral valve anomalies	LBBB	Transvenous	67	57	208	134	30	45	40	Responders	Live	19
13	3.5	ccTGA	Ventricular Dysfunction	Epicardial	62	58	124	104	36	45	45	Responders	Live	68
14	2.2	VSD	PM induced	Epicardial	64	52	148	102	26	65	65	Superresponders	Live	62
15	18	ccTGA	Ventricular Dysfunction	Epicardial	70	68	224	148	20	45	50	Responders	Live	75
16	18	ASD	PM induced	Hybrid	65	50	170	100	29	70	70	Superresponders	Live	7
17	12.5	VSD	LBBB	Epicardial	67	59	140	90	44	55	55	Responders	Live	6
18	17	Aortic stenosis	PM induced	Epicardial	65	60	160	130	35	49	50	Responders	Live	9

ASD=atrial septal defect; AVSD=atrio ventricular septal defect; ccTGA=congenitally corrected transposition of the great arteries; CRT=cardiac resynchronization therapy; CTR=cardiothoracic ratio; LBBB=left bundle branch block; NYHA=New York heart association; PM=pacemaker; TOF=tetralogy of Fallot; VSD=ventricular septal defect

\*Quantitative improvement and/or subjective improvement of the functional class: symptoms of patients 1, 5, 7, 8, 12, 14, 15, 16, 18 decreased and Patient 1 (NYHA Class 3–2); Patient 5 (NYHA Class 3–2); Patient 7 (Ross Class 3–2); Patient 8 (Ross Class 4–3); Patient 12 (NYHA Class 3–1); Patient 14 (Ross Class 4–2); Patient 16 (NYHA Class 4–2); Patient 18 (NYHA Class 4–3)

In our study, ventricular pacing was upgraded to CRT in 11 cases (9 RV and 2 LV pacing; 61%). An improvement in ventricular systolic functions was detected in all of the cases (10/11; 90%) except one.

Apart from pacing, dyssynchronisation can also be seen in patients with LBBB, RBBB, preexcitation, and frequent premature ventricular contractions and consequently ventricular dysfunction has been observed.<sup>12</sup> Janoušek et al reported LBBB in 10% of cases and RBBB in 5% of cases in their CRT series.<sup>14</sup>

In our study, LBBB was determined in four patients (22%) and RBBB in three patients (16%). These rates were higher than Janoušek et al, which might be due to the diagnostic and demographic differences in cases with CHD.

In cases with CHD with functional two ventricles, the right ventricle is the systemic ventricle in cases of ccTGA and after intra-atrial baffle operation in the transposition of the great arteries. At least a moderate degree of heart failure or exercise intolerance was reported in one-third of these cases. Systemic RV heart failure is an important cause of late morbidity in CHD.<sup>18</sup> The contribution of CRT in regression of heart failure symptoms in these cases has been controversial. In a study of eight CRT cases, Janoušek et al assessed haemodynamic effects in systemic RV cases, and found a 10% increase in right ventricular EF and right ventricular fractional area of change increased from 18 to 30% in 17.5 months.<sup>19</sup> Cecchin et al in a series of nine cases with systemic RV, reported that EF increased from 28 to 42% in the first 30 days, however, in the long term, only two cases showed response and seven were non-responsive.<sup>8</sup> In our study, there were four cases with systemic RV. CRT was used due to PIVD in one of them and for systemic ventricular dysfunction in the rest. In these three cases, there was an increase in EF and response in clinical status.

Patients with single-ventricle physiology are at risk of developing heart failure, associated with increased mortality. Myocardial dysfunction is one of the important causes of mortality after bidirectional cavopulmonary anastomosis and Fontan operation.<sup>20</sup> In a patient group of single ventricle with post-Fontan palliation, followed for a median of 17 years, 40% developed congestive heart failure and 18% died.<sup>21</sup> It has been suggested that CRT for intraventricular resynchronisation in these cases should be performed through multisite pacing. Bacha EA et al reported that out of 26 patients whom CRT via multisite pacing was performed, haemodynamic improvement was observed in 24 patients in the early period.<sup>22</sup> However, in a series of patients reported for the long term, the rate of CRT application in single ventricular physiology is quite low. For example, Janousek<sup>14</sup> reported that 3.7% of 109 CRT patients had single ventricular physiology and Dubin<sup>13</sup> reported this rate as 6.8% of 103 CRT cases. In our study, this rate was 6% which was compatible with other publications.

In the literature, different techniques such as epicardial, transvenous, or hybrid method were used according to patient age, pathology, or the single versus dual-chamber feature of the previous pacemaker.<sup>8,23–25</sup> In our study, the epicardial method (72%) was used in majority of the cases.

Echocardiographic and ECG parameters are frequently used in the long-term follow-up of patients and prognosis of CRT.<sup>21,26</sup> There is insufficient data on which of these may be a stronger predictor. Although prolonged QRS duration appeared to be a criterion for CRT application in adult studies, it was also reported that it may not be a good predictor in some studies.<sup>5</sup> Echocardiography has been frequently used to detect mechanical dyssynchrony, and many parameters have been proposed for that purpose in children with

CHD.<sup>27</sup> However, ventricular geometry, systemic ventricular morphology, and bundle branch block can lead to misinterpretation of results. In the Japanese multicentre study, a single echocardiography criterion was not found for prediction, and the combination of M mode measurement of the left ventricle and tissue Doppler USG was reported to be beneficial in patients with LBBB on ECG.<sup>28</sup> Punn et al by comparing ECHO and ECG in optimisation of CRT stated that ECHO did not show superiority in their studies, and ECG was more advantageous considering the duration and cost of the procedure.<sup>29</sup> In our study, we achieved optimisation by using ECG QRS duration and echocardiographic dyssynchrony measurements and EF change as a basis for follow-up. 3D ECHO and strain ECHO were also used when it was available during the last 4 years.

In different studies, the incidence of responses varied according to the age at the CRT application and ventricular morphology. Five different clinical responses were reported to be possible, namely superresponders, responders, non-progressors, non-responders, negative corresponders.<sup>30</sup> The ideal for prognosis was the superresponder, where the anatomy and function became normal with clinical improvement and reverse remodeling after CRT. In our population, 11% of the patients treated with CRT for refractory heart failure could be identified as superresponders. This proportion was similar to previously reported results, ranging from 12 to 16%.<sup>12,22,25</sup> Our non-responder rate was 11%. Independent of ventricular physiology, previous mitral valve replacement, left ventricular non-compaction, and aortic stenosis might have contributed to the two cases who did not respond. This rate was reported as 30% in the adult series of Young et al<sup>31</sup> and 10–18% in the largest paediatric series.<sup>13,14</sup>

Despite the benefits of CRT including improvements in exercise capacity, functional class, and ventricular haemodynamics, a proarrhythmic effect is less clear. The fact that patients have CRT might lead to increased risk for ventricular tachycardia in some reports. At the same time, sudden cardiac death risk was increased in CRT patients when the ventricular functions were taken into consideration. Randomised trial evidence directly comparing cardiac resynchronization therapy (CRT) with a pacemaker (CRT-P) and with an implantable defibrillator (CRT-D) is not available. Indirect evidence suggests that CRT-D may reduce mortality to a greater degree because of greater sudden death reduction. CRT-D is more costly and possibly subject to more complications than CRT-P.<sup>32,33</sup> All three of the patients who had CRT-D implanted in our study had a high risk for sudden death before the implantation. We did not encounter any proarrhythmic situation in patients with CRT-P implantation. Only the patient with aortic stenosis (whose VT was not documented previously but had CRT-D implantation due to syncope) had sustained VT episodes during follow-up. He was followed up with medical treatment. Therefore, it might not be too correct to say that CRT has a proarrhythmic effect according to the results of our study. It seems larger studies with longer follow-up periods are needed about this subject. The emergence of possible arrhythmia risk may lead us to use CRT-D in paediatric cases.

### Limitations

This study had several limitations. The sample size was small, and the basic cardiac anomalies were heterogeneous. The lack of evaluation of functional capacity in cases in the paediatric age group was another shortcoming. In addition, cardiac function and ventricular volume could be evaluated more accurately by cardiac magnetic resonance (MR) examination, especially in those without systemic

ventricle left ventricle. However, this technique was not technically possible in patients who underwent epicardial or hybrid CRT. Although total follow-up duration was longer, for the sake of standardisation, the individual CRT response of the patients were given at a shorter period of 6–12 months and this was another limitation of the study.

## Conclusion

Patients with highly heterogeneous and complex CHD might develop heart failure early or late. Electromechanical dyssynchrony is one of the factors in the development of heart failure in patients with CHD. Patients with CHD and wide QRS complexes should thus be specifically screened for a CRT indication. If properly applied, CRT causes reverse ventricular remodelling, augments systolic ventricular functions, and may improve long-term prognosis.

**Acknowledgements.** None.

**Financial support.** This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

**Conflict of interest.** None.

**Authors' contribution.** YE: Conception or design of the work, drafting the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. FSS: Conception or design of the work, drafting the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. EO: Conception or design of the work, drafting the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. CK: Revising the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. PA: Conception or design of the work, drafting the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. CT: Conception or design of the work, Ddrafting the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. SA: Conception or design of the work, drafting the work, fFinal approval of the version to be published, any part of the work are appropriately investigated and resolved. MG: Conception or design of the work, drafting the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. OY: Conception or design of the work, drafting the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved. SH: Acquisition and analysis, final approval of the version to be published, any part of the work are appropriately investigated and resolved. AG: Conception or design of the work, revising the work, final approval of the version to be published, any part of the work are appropriately investigated and resolved.

**Ethical standards.** The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guidelines on human experimentation and with the Helsinki Declaration of 1975 and the Istanbul Mehmet Akif Ersoy Research and Training Hospital Institutional Review Board (124-2011MAEH) approved the study.

## References

- Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005; 352: 1539–1549.
- Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. *Circulation* 2013; 128: e240–e327.
- Motonaga KS, Dubin AM. Cardiac resynchronization therapy for pediatric patients with heart failure and congenital heart disease: a reappraisal of results. *Circulation* 2014; 129: 1879–1891.
- Tworetzky W, McElhinney DB, Brook MM, et al. Echocardiographic diagnosis alone for the complete repair of major congenital heart defects. *J Am Coll Cardiol* 1999; 33: 228–333.
- Karpawich PP, Bansal N, Samuel S, et al. 16 years of cardiac resynchronization pacing among congenital heart disease patients: direct contractility (dP/dt-max) screening when the guidelines do not apply. *JACC Clin Electrophysiol* 2017; 3: 830–841.
- Anjewierden S, Aziz PF. Resynchronization therapy for patients with congenital heart disease: are we ready for prime time? *Curr Cardiol Rep* 2018; 20: 75.
- Hill AC, Silka MJ, Bar-Cohen Y. Cardiac resynchronization therapy in pediatrics. *J Innov Card Rhythm Manag* 2018; 9: 3256–3264.
- Cecchin F, Frangini PA, Brown DW, et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: 5 years experience in a single institution. *J Cardiovasc Electrophysiol* 2009; 20: 58–65.
- Pearlman AS, Gardin JM, Martin RP, et al. Guidelines for optimal physician training in echocardiography. Recommendations of the American society of echocardiography committee for physician training in echocardiography. *Am J Cardiol* 1987; 60: 158–163.
- Van der Hulst AE, Delgado V, Blom NA, et al. Cardiac resynchronization therapy in paediatric and congenital heart disease patients. *Eur Heart J* 2011; 32: 2236–2246.
- Steffel J, Ruschitzka F. Superresponse to cardiac resynchronization therapy. *Circulation* 2014; 130: 87–90.
- Batra AS, Balaji S. Cardiac resynchronization therapy in children. *Curr Cardiol Rev* 2009; 5: 40–44.
- Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. *J Am Coll Cardiol* 2005; 46: 2277–2283.
- Janousek J, Gebauer RA, Abdul-Khaliq H, et al. Cardiac resynchronization therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. *Heart* 2009; 95: 1165–1171.
- Perera JL, Motonaga KS, Miyake CY, et al. Does pediatric CRT increase the risk of ventricular tachycardia? *Heart Rhythm* 2013; 10: 210–211.
- Valsangiocomo E, Schmid ER, Schüpbach RW, et al. Early postoperative arrhythmias after cardiac operation in children. *Ann Thorac Surg* 2002; 74: 792–796.
- Balaji S, Sreeram N. The development of pacing induced ventricular dysfunction is influenced by the underlying structural heart defect in children with congenital heart disease. *Indian Heart J* 2017; 69: 240–243.
- Khairy P, Landzberg MJ, Lambert J, et al. Long-term outcomes after atrial switch for transposition of the great arteries: a meta-analysis comparing Mustard and Senning procedures. *Cardiol Young* 2004; 14: 284–292.
- Janousek J, Tomek V, Chaloupecky VA, et al. Cardiac resynchronization therapy: a novel adjunct to the treatment and prevention of systemic right ventricular failure. *J Am Coll Cardiol* 2004; 44: 1927–1931.
- Kiaffas MG, Van Praagh R, Hanioti C, et al. The modified Fontan procedure: morphometry and surgical implications. *Ann Thorac Surg* 1999; 67: 1746–1753.
- Piran S, Veldtman G, Siu S, et al. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. *Circulation* 2002; 105: 1189–1194.
- Bacha EA, Zimmerman FJ, Mor-Avi V, et al. Ventricular resynchronization by multisite pacing improves myocardial performance in the postoperative single-ventricle patient. *Ann Thorac Surg* 2004; 78: 1678–1683.
- Miyazaki A, Negishi J, Hayama Y, et al. Evaluating the response to cardiac resynchronization therapy performed with a new ventricular morphology-based strategy for congenital heart disease. *Heart Vessels* 2019; 34: 1340–1350.
- Kubus P, Materna O, Gebauer RA, et al. Permanent epicardial pacing in children: long-term results and factors modifying outcome. *Europace* 2012; 14: 509–514.
- Miyazaki A, Sakaguchi H, Kagisaki K, et al. Optimal pacing sites for cardiac resynchronization therapy for patients with a systemic right ventricle with or without a rudimentary left ventricle. *Europace* 2016; 18: 100–112.



26. Sakaguchi H, Miyazaki A, Yamada O, et al. Cardiac resynchronization therapy for various systemic ventricular morphologies in patients with congenital heart disease. *Circ J* 2015; 79: 649–655.
27. Friedberg MK, Mertens L. Echocardiographic assessment of ventricular-synchrony in congenital and acquired heart disease in children. *Echocardiography* 2013; 30: 460–471.
28. Seo Y, Ito H, Nakatani S, et al. J-CRTinvestigators. The role of echocardiography in predicting respondersto cardiac resynchronization therapy. *Circ J* 2011; 75: 1156–1163.
29. Punn R, Hanisch D, Motonaga KS, et al. A pilot study assessing ECG versus ECHO ventriculoventricular optimization in pediatric resynchronization patients. *J Cardiovasc Electrophysiol* 2016; 27: 210–216.
30. Horigome H. Current status and future direction of cardiac resynchronization therapy for congenital heart disease and pediatric patients. *Circ J* 2014; 78: 1579–1581.
31. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillationin advanced chronic heart failure: the MIRACLE ICD trial. *JAMA* 2003; 289: 2685–2694.
32. Horigome H. Current status and future direction of cardiac resynchronization therapy for congenital heart disease and pediatric patients. *Circ J* 2014; 78: 1579–1581.
33. Ray Basu, Fendelander L, Singh JP. Cardiac resynchronization therapy and its potential proarrhythmic effect. *Clin Cardiol* 2007; 30: 498–502.